Open AccessAbstract 1813: Bevacizumab potentiates the proteomic response to neoadjuvant chemotherapy in breast cancer patients: Rppa exploration of consecutive tumor samples in the NeoAva randomized phase II trial
Author(s) -
Mads H. Haugen,
Ole Christian Lingjærde,
Marit Krohn,
Wei Zhao,
Evita M. Lindholm,
Laxmi Silwal-Pandit,
Elin Borgen,
Øystein Garred,
Anne Fangberget,
Marit Muri Holmen,
Ellen Schlichting,
Helle Skjerven,
Steinar Lundgren,
Erik Wist,
Bjørn Naume,
Gunhild Mari Mælandsmo,
Yiling Lu,
Anne-Lise Boerresen-Dale,
Gordon B. Mills,
Olav Engebraaten
Publication year - 2017
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2017-1813
Subject(s) - bevacizumab , medicine , taxane , oncology , breast cancer , chemotherapy , cancer , targeted therapy , response evaluation criteria in solid tumors , neoadjuvant therapy , randomized controlled trial , clinical trial , phases of clinical research , pathology